Tag:
overtime pay
Latest Headlines
Latest Headlines
GSK, sales rep lawyers argue OT case at Supreme Court
The U.S. Supreme Court hears arguments today in the sales-rep overtime case pitting pharma salespeople against GlaxoSmithKline.
More reps sue Novo for back overtime
Another batch of sales reps has sued Novo Nordisk ( $NVO ) for overtime. The would-be class action suit, which was filed by two reps, is seeking $70 million in overtime pay. Like so many other lawsuits--pending and otherwise--this one alleges a drugmaker misclassified its reps as exempt salaried workers when they should have been eligible for overtime.
LEO Pharma slapped with sales-rep overtime suit
The sales-rep overtime fight is spreading. Four LEO Pharma salespeople have filed a putative class action, alleging they're owed overtime under U.S. wage-and-hour laws. The reps accuse LEO of...
Supreme Court will hear sales-rep overtime dispute
The U.S. Supreme Court is ready for a showdown on sales-rep overtime. The court agreed to hear an appeal in GlaxoSmithKline's ( $GSK ) overtime case that was filed by two former reps seeking back pay
GSK reps take OT suit to U.S. Supreme Court
The U.S. Supreme Court may just decide this pharma-rep overtime issue once and for all. Two GlaxoSmithKline ( $GSK ) reps who lost their suit for back overtime pay on appeal are asking the Supremes to
S-P sales reps win another OT round
Chalk up another victory for sales reps in their fight for overtime pay. A U.S. judge has decided that Schering-Plough sales people don't qualify for the administrative exemption under U.S. labor
Judge deems Boehringer rep eligible for OT pay
Time to update your sales-rep overtime scorecard. A federal judge has ruled that a Boehringer Ingelheim rep is not exempt from overtime pay under the Fair Labor Standards Act, Pharmalot reports. It's
Laid-off Pfizer reps join OT lawsuit
Chalk this up to unintended consequences. Laid-off Pfizer sales reps are flocking to a longstanding class action seeking back overtime pay, BNet Pharma reports. Pfizer's moves to pare back its sales
